DK2581097T3 - Compositions for preventing adhesions and other barrier applications - Google Patents

Info

Publication number

DK2581097T3

DK2581097T3 DK12196176.7T DK12196176T DK2581097T3 DK 2581097 T3 DK2581097 T3 DK 2581097T3 DK 12196176 T DK12196176 T DK 12196176T DK 2581097 T3 DK2581097 T3 DK 2581097T3

Authority

DK

Denmark

Prior art keywords

self

peptides

assembling peptides

amino acid

assembling

Prior art date

2007-04-25

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 title claims description 257
• 230000004888 barrier function Effects 0.000 title claims description 31
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 450
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 343
• 238000000034 method Methods 0.000 claims description 111
• 210000001519 tissue Anatomy 0.000 claims description 105
• 208000027418 Wounds and injury Diseases 0.000 claims description 77
• 238000001356 surgical procedure Methods 0.000 claims description 73
• 125000000539 amino acid group Chemical group 0.000 claims description 53
• 208000014674 injury Diseases 0.000 claims description 45
• 229920000642 polymer Polymers 0.000 claims description 45
• 210000004027 cell Anatomy 0.000 claims description 44
• 230000006378 damage Effects 0.000 claims description 44
• 239000000126 substance Substances 0.000 claims description 39
• 210000000936 intestine Anatomy 0.000 claims description 36
• 239000007788 liquid Substances 0.000 claims description 34
• 239000000499 gel Substances 0.000 claims description 32
• 239000000843 powder Substances 0.000 claims description 28
• 150000002500 ions Chemical class 0.000 claims description 27
• 239000003814 drug Substances 0.000 claims description 26
• 238000000576 coating method Methods 0.000 claims description 24
• 239000011248 coating agent Substances 0.000 claims description 23
• 210000004185 liver Anatomy 0.000 claims description 22
• 210000004369 blood Anatomy 0.000 claims description 20
• 239000008280 blood Substances 0.000 claims description 20
• 239000011159 matrix material Substances 0.000 claims description 19
• 210000004204 blood vessel Anatomy 0.000 claims description 16
• 239000000017 hydrogel Substances 0.000 claims description 15
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 14
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 14
• 210000002744 extracellular matrix Anatomy 0.000 claims description 14
• 239000003102 growth factor Substances 0.000 claims description 13
• 210000004556 brain Anatomy 0.000 claims description 12
• 210000002784 stomach Anatomy 0.000 claims description 12
• 210000004072 lung Anatomy 0.000 claims description 10
• 210000003205 muscle Anatomy 0.000 claims description 10
• 210000001124 body fluid Anatomy 0.000 claims description 9
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
• 239000000839 emulsion Substances 0.000 claims description 9
• 239000006260 foam Substances 0.000 claims description 9
• 239000005526 vasoconstrictor agent Substances 0.000 claims description 9
• 210000003462 vein Anatomy 0.000 claims description 9
• 102000008186 Collagen Human genes 0.000 claims description 8
• 108010035532 Collagen Proteins 0.000 claims description 8
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
• 239000004599 antimicrobial Substances 0.000 claims description 8
• 229920001436 collagen Polymers 0.000 claims description 8
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
• 230000003444 anaesthetic effect Effects 0.000 claims description 7
• 239000007921 spray Substances 0.000 claims description 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
• 210000001367 artery Anatomy 0.000 claims description 6
• 210000000941 bile Anatomy 0.000 claims description 6
• 230000007935 neutral effect Effects 0.000 claims description 6
• 235000015097 nutrients Nutrition 0.000 claims description 6
• 239000002674 ointment Substances 0.000 claims description 6
• 239000006071 cream Substances 0.000 claims description 5
• 210000003238 esophagus Anatomy 0.000 claims description 5
• 239000011859 microparticle Substances 0.000 claims description 5
• 241001269524 Dura Species 0.000 claims description 4
• 210000002249 digestive system Anatomy 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 210000000416 exudates and transudate Anatomy 0.000 claims description 4
• 210000000653 nervous system Anatomy 0.000 claims description 4
• 210000000496 pancreas Anatomy 0.000 claims description 4
• 210000004994 reproductive system Anatomy 0.000 claims description 4
• 210000000278 spinal cord Anatomy 0.000 claims description 4
• 210000002700 urine Anatomy 0.000 claims description 4
• 210000000748 cardiovascular system Anatomy 0.000 claims description 3
• 239000003973 paint Substances 0.000 claims description 3
• 210000003800 pharynx Anatomy 0.000 claims description 3
• 210000004915 pus Anatomy 0.000 claims description 3
• 210000002345 respiratory system Anatomy 0.000 claims description 3
• 239000002002 slurry Substances 0.000 claims description 3
• 230000003872 anastomosis Effects 0.000 claims description 2
• 210000001508 eye Anatomy 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 210000001635 urinary tract Anatomy 0.000 claims description 2
• 239000010839 body fluid Substances 0.000 claims 3
• 210000004211 gastric acid Anatomy 0.000 claims 1
• 230000010354 integration Effects 0.000 claims 1
• 230000003137 locomotive effect Effects 0.000 claims 1
• 239000000463 material Substances 0.000 description 117
• -1 anti-infectives Substances 0.000 description 87
• 208000032843 Hemorrhage Diseases 0.000 description 71
• 208000034158 bleeding Diseases 0.000 description 70
• 230000000740 bleeding effect Effects 0.000 description 70
• 239000000243 solution Substances 0.000 description 68
• 238000009472 formulation Methods 0.000 description 51
• 230000023597 hemostasis Effects 0.000 description 49
• 206010052428 Wound Diseases 0.000 description 44
• 150000001413 amino acids Chemical class 0.000 description 39
• 230000033001 locomotion Effects 0.000 description 36
• 229940024606 amino acid Drugs 0.000 description 32
• 235000001014 amino acid Nutrition 0.000 description 31
• 230000002209 hydrophobic effect Effects 0.000 description 30
• 239000003795 chemical substances by application Substances 0.000 description 28
• 239000007787 solid Substances 0.000 description 28
• 238000011282 treatment Methods 0.000 description 28
• 239000012530 fluid Substances 0.000 description 27
• 210000000056 organ Anatomy 0.000 description 27
• 230000008439 repair process Effects 0.000 description 26
• 210000003491 skin Anatomy 0.000 description 26
• 230000015572 biosynthetic process Effects 0.000 description 25
• 235000002639 sodium chloride Nutrition 0.000 description 25
• 238000001338 self-assembly Methods 0.000 description 24
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
• 239000003826 tablet Substances 0.000 description 22
• 208000015181 infectious disease Diseases 0.000 description 21
• 239000002243 precursor Substances 0.000 description 21
• 239000011780 sodium chloride Substances 0.000 description 21
• 230000001225 therapeutic effect Effects 0.000 description 20
• 150000001875 compounds Chemical class 0.000 description 19
• 238000011109 contamination Methods 0.000 description 18
• 239000002552 dosage form Substances 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 230000003993 interaction Effects 0.000 description 17
• 239000004005 microsphere Substances 0.000 description 17
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• 230000035876 healing Effects 0.000 description 16
• 241000700159 Rattus Species 0.000 description 15
• 239000003086 colorant Substances 0.000 description 15
• 231100000241 scar Toxicity 0.000 description 15
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 206010028980 Neoplasm Diseases 0.000 description 13
• 208000025865 Ulcer Diseases 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• 230000004962 physiological condition Effects 0.000 description 13
• 231100000397 ulcer Toxicity 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 239000003085 diluting agent Substances 0.000 description 12
• 239000003921 oil Substances 0.000 description 12
• 235000019198 oils Nutrition 0.000 description 12
• 235000018102 proteins Nutrition 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 108090000623 proteins and genes Proteins 0.000 description 12
• 206010002329 Aneurysm Diseases 0.000 description 11
• 241000894006 Bacteria Species 0.000 description 11
• 230000000295 complement effect Effects 0.000 description 11
• 210000003736 gastrointestinal content Anatomy 0.000 description 11
• 239000012678 infectious agent Substances 0.000 description 11
• 239000012071 phase Substances 0.000 description 11
• 230000007704 transition Effects 0.000 description 11
• 150000001720 carbohydrates Chemical group 0.000 description 10
• 229920001577 copolymer Polymers 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 230000002496 gastric effect Effects 0.000 description 10
• 239000001257 hydrogen Substances 0.000 description 10
• 229910052739 hydrogen Inorganic materials 0.000 description 10
• 230000000069 prophylactic effect Effects 0.000 description 10
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• 210000001015 abdomen Anatomy 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 239000011230 binding agent Substances 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 125000000524 functional group Chemical group 0.000 description 9
• 239000003193 general anesthetic agent Substances 0.000 description 9
• 239000000816 peptidomimetic Substances 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 238000002271 resection Methods 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 229920002472 Starch Polymers 0.000 description 8
• 239000000853 adhesive Substances 0.000 description 8
• 230000001070 adhesive effect Effects 0.000 description 8
• 229920000615 alginic acid Polymers 0.000 description 8
• 235000010443 alginic acid Nutrition 0.000 description 8
• 125000000217 alkyl group Chemical group 0.000 description 8
• 235000014633 carbohydrates Nutrition 0.000 description 8
• 238000004132 cross linking Methods 0.000 description 8
• 238000013265 extended release Methods 0.000 description 8
• 230000000968 intestinal effect Effects 0.000 description 8
• 239000000314 lubricant Substances 0.000 description 8
• 229910052751 metal Inorganic materials 0.000 description 8
• 239000002184 metal Substances 0.000 description 8
• 239000002245 particle Substances 0.000 description 8
• 235000019698 starch Nutrition 0.000 description 8
• 230000008733 trauma Effects 0.000 description 8
• 230000002792 vascular Effects 0.000 description 8
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 7
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
• 108091034117 Oligonucleotide Proteins 0.000 description 7
• 108091005804 Peptidases Proteins 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 229940072056 alginate Drugs 0.000 description 7
• 125000003277 amino group Chemical group 0.000 description 7
• 239000003242 anti bacterial agent Substances 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000000975 bioactive effect Effects 0.000 description 7
• 150000001768 cations Chemical class 0.000 description 7
• 229920002678 cellulose Polymers 0.000 description 7
• 239000001913 cellulose Substances 0.000 description 7
• 230000007547 defect Effects 0.000 description 7
• 210000001105 femoral artery Anatomy 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 229910052742 iron Inorganic materials 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 229920003023 plastic Polymers 0.000 description 7
• 239000004033 plastic Substances 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 229920001059 synthetic polymer Polymers 0.000 description 7
• 210000000538 tail Anatomy 0.000 description 7
• 239000001856 Ethyl cellulose Substances 0.000 description 6
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 230000003115 biocidal effect Effects 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 235000010980 cellulose Nutrition 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 229940039227 diagnostic agent Drugs 0.000 description 6
• 239000000032 diagnostic agent Substances 0.000 description 6
• 238000009792 diffusion process Methods 0.000 description 6
• 238000012377 drug delivery Methods 0.000 description 6
• 229920001249 ethyl cellulose Polymers 0.000 description 6
• 235000019325 ethyl cellulose Nutrition 0.000 description 6
• 239000008187 granular material Substances 0.000 description 6
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
• 238000007912 intraperitoneal administration Methods 0.000 description 6
• 229960004194 lidocaine Drugs 0.000 description 6
• 239000012669 liquid formulation Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• 210000003200 peritoneal cavity Anatomy 0.000 description 6
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000037390 scarring Effects 0.000 description 6
• 239000003381 stabilizer Substances 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 229940032147 starch Drugs 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 241000233866 Fungi Species 0.000 description 5
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
• 241001582888 Lobus Species 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 239000000730 antalgic agent Substances 0.000 description 5
• 239000012620 biological material Substances 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 125000001165 hydrophobic group Chemical group 0.000 description 5
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 5
• 125000005647 linker group Chemical group 0.000 description 5
• 239000003589 local anesthetic agent Substances 0.000 description 5
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 239000004014 plasticizer Substances 0.000 description 5
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
• 230000001737 promoting effect Effects 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000004094 surface-active agent Substances 0.000 description 5
• 239000001993 wax Substances 0.000 description 5
• 230000029663 wound healing Effects 0.000 description 5
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 description 4
• 102000015336 Nerve Growth Factor Human genes 0.000 description 4
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
• 229920002732 Polyanhydride Polymers 0.000 description 4
• 206010063837 Reperfusion injury Diseases 0.000 description 4
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
• 229920002125 Sokalan® Polymers 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 108010009583 Transforming Growth Factors Proteins 0.000 description 4
• 102000009618 Transforming Growth Factors Human genes 0.000 description 4
• 238000005299 abrasion Methods 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 230000023555 blood coagulation Effects 0.000 description 4
• 238000002983 circular dichroism Methods 0.000 description 4
• 239000008199 coating composition Substances 0.000 description 4
• 239000000356 contaminant Substances 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• 230000003111 delayed effect Effects 0.000 description 4
• 239000000645 desinfectant Substances 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 230000003628 erosive effect Effects 0.000 description 4
• 208000024170 esophageal varices Diseases 0.000 description 4
• 201000010120 esophageal varix Diseases 0.000 description 4
• 229920001002 functional polymer Polymers 0.000 description 4
• 150000004676 glycans Chemical class 0.000 description 4
• 230000036571 hydration Effects 0.000 description 4
• 238000006703 hydration reaction Methods 0.000 description 4
• 229920001477 hydrophilic polymer Polymers 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 210000002429 large intestine Anatomy 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 229940053128 nerve growth factor Drugs 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 210000001819 pancreatic juice Anatomy 0.000 description 4
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
• 229960001802 phenylephrine Drugs 0.000 description 4
• 239000000049 pigment Substances 0.000 description 4
• 229920001282 polysaccharide Polymers 0.000 description 4
• 239000005017 polysaccharide Substances 0.000 description 4
• 239000011148 porous material Substances 0.000 description 4
• 235000019419 proteases Nutrition 0.000 description 4
• 230000008929 regeneration Effects 0.000 description 4
• 238000011069 regeneration method Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 238000007789 sealing Methods 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 229940083542 sodium Drugs 0.000 description 4
• 238000005507 spraying Methods 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
• 210000000798 superior sagittal sinus Anatomy 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000017423 tissue regeneration Effects 0.000 description 4
• MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 4
• 230000002485 urinary effect Effects 0.000 description 4
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
• 229920002126 Acrylic acid copolymer Polymers 0.000 description 3
• ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• 101800001148 Delta-peptide Proteins 0.000 description 3
• 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010061216 Infarction Diseases 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• 102400000058 Neuregulin-1 Human genes 0.000 description 3
• 108090000556 Neuregulin-1 Proteins 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 208000004210 Pressure Ulcer Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
• 208000002847 Surgical Wound Diseases 0.000 description 3
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
• 206010056091 Varices oesophageal Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000003187 abdominal effect Effects 0.000 description 3
• 238000012084 abdominal surgery Methods 0.000 description 3
• 229940035674 anesthetics Drugs 0.000 description 3
• 230000002924 anti-infective effect Effects 0.000 description 3
• 229960005475 antiinfective agent Drugs 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000010478 bone regeneration Effects 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
• 210000001736 capillary Anatomy 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 125000002843 carboxylic acid group Chemical group 0.000 description 3
• 210000000845 cartilage Anatomy 0.000 description 3
• 238000005266 casting Methods 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 238000004140 cleaning Methods 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000008602 contraction Effects 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 238000012864 cross contamination Methods 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 208000000718 duodenal ulcer Diseases 0.000 description 3
• 210000001198 duodenum Anatomy 0.000 description 3
• 210000001951 dura mater Anatomy 0.000 description 3
• 238000005538 encapsulation Methods 0.000 description 3
• 208000001780 epistaxis Diseases 0.000 description 3
• 239000004744 fabric Substances 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 210000004051 gastric juice Anatomy 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 208000014617 hemorrhoid Diseases 0.000 description 3
• 239000008241 heterogeneous mixture Substances 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
• 230000007574 infarction Effects 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 206010022694 intestinal perforation Diseases 0.000 description 3
• 238000007913 intrathecal administration Methods 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000006193 liquid solution Substances 0.000 description 3
• 239000008176 lyophilized powder Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
• 239000003094 microcapsule Substances 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 238000002324 minimally invasive surgery Methods 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 206010033675 panniculitis Diseases 0.000 description 3
• 238000005192 partition Methods 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
• 229920000573 polyethylene Polymers 0.000 description 3
• 229920002451 polyvinyl alcohol Polymers 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 238000007388 punch biopsy Methods 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000010410 reperfusion Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 239000010703 silicon Substances 0.000 description 3
• 210000003625 skull Anatomy 0.000 description 3
• 238000000935 solvent evaporation Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 229920000428 triblock copolymer Polymers 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• 238000012800 visualization Methods 0.000 description 3
• 239000011782 vitamin Substances 0.000 description 3
• 229940088594 vitamin Drugs 0.000 description 3
• 229930003231 vitamin Natural products 0.000 description 3
• 235000013343 vitamin Nutrition 0.000 description 3
• 239000011800 void material Substances 0.000 description 3
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
• LMBABJNSZGKTBA-UHFFFAOYSA-N 3,6-bis[(4-chloro-2-phosphonophenyl)diazenyl]-4,5-dihydroxynaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C(=CC(Cl)=CC=3)P(O)(O)=O)C(O)=C2C(O)=C1N=NC1=CC=C(Cl)C=C1P(O)(O)=O LMBABJNSZGKTBA-UHFFFAOYSA-N 0.000 description 2
• 206010000050 Abdominal adhesions Diseases 0.000 description 2
• 241000220479 Acacia Species 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• 239000005995 Aluminium silicate Substances 0.000 description 2
• 206010003012 Appendicitis perforated Diseases 0.000 description 2
• 206010003497 Asphyxia Diseases 0.000 description 2
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
• 229930186147 Cephalosporin Natural products 0.000 description 2
• 206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 2
• 229920002101 Chitin Polymers 0.000 description 2
• 229920001661 Chitosan Polymers 0.000 description 2
• 206010053567 Coagulopathies Diseases 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• AGPKZVBTJJNPAG-CRCLSJGQSA-N D-allo-isoleucine Chemical compound CC[C@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-CRCLSJGQSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010011985 Decubitus ulcer Diseases 0.000 description 2
• 206010056340 Diabetic ulcer Diseases 0.000 description 2
• NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 206010017815 Gastric perforation Diseases 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
• 208000031220 Hemophilia Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
• 208000034693 Laceration Diseases 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 108010003541 Platelet Activating Factor Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 2
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 2
• 239000004952 Polyamide Substances 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 208000035965 Postoperative Complications Diseases 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 208000007107 Stomach Ulcer Diseases 0.000 description 2
• 208000033809 Suppuration Diseases 0.000 description 2
• ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
• 238000005411 Van der Waals force Methods 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 229930003448 Vitamin K Natural products 0.000 description 2
• 229920002494 Zein Polymers 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 125000002009 alkene group Chemical group 0.000 description 2
• 125000002355 alkine group Chemical group 0.000 description 2
• 235000012211 aluminium silicate Nutrition 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 238000004873 anchoring Methods 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 238000002583 angiography Methods 0.000 description 2
• 239000003945 anionic surfactant Substances 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 229940127219 anticoagulant drug Drugs 0.000 description 2
• 210000000709 aorta Anatomy 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 239000003899 bactericide agent Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 239000003114 blood coagulation factor Substances 0.000 description 2
• 230000036760 body temperature Effects 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 235000013539 calcium stearate Nutrition 0.000 description 2
• 239000008116 calcium stearate Substances 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
• 229920003086 cellulose ether Polymers 0.000 description 2
• 229940124587 cephalosporin Drugs 0.000 description 2
• 150000001780 cephalosporins Chemical class 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• SXYCCJAPZKHOLS-UHFFFAOYSA-N chembl2008674 Chemical compound [O-][N+](=O)C1=CC=C2C(N=NC3=C4C=CC=CC4=CC=C3O)=C(O)C=C(S(O)(=O)=O)C2=C1 SXYCCJAPZKHOLS-UHFFFAOYSA-N 0.000 description 2
• 230000003399 chemotactic effect Effects 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 238000002316 cosmetic surgery Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 238000005520 cutting process Methods 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 229960003067 cystine Drugs 0.000 description 2
• 238000001804 debridement Methods 0.000 description 2
• 239000008367 deionised water Substances 0.000 description 2
• 229910021641 deionized water Inorganic materials 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
• RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 210000003722 extracellular fluid Anatomy 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 239000000383 hazardous chemical Substances 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 239000008240 homogeneous mixture Substances 0.000 description 2
• 239000012943 hotmelt Substances 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 238000009802 hysterectomy Methods 0.000 description 2
• 210000003090 iliac artery Anatomy 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 229910010272 inorganic material Inorganic materials 0.000 description 2
• 239000011147 inorganic material Substances 0.000 description 2
• 208000003243 intestinal obstruction Diseases 0.000 description 2
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000011344 liquid material Substances 0.000 description 2
• 229960005015 local anesthetics Drugs 0.000 description 2
• 238000009593 lumbar puncture Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 125000005395 methacrylic acid group Chemical group 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• LJYRLGOJYKPILZ-UHFFFAOYSA-N murexide Chemical compound [NH4+].N1C(=O)NC(=O)C(N=C2C(NC(=O)NC2=O)=O)=C1[O-] LJYRLGOJYKPILZ-UHFFFAOYSA-N 0.000 description 2
• 210000002346 musculoskeletal system Anatomy 0.000 description 2
• 239000002086 nanomaterial Substances 0.000 description 2
• 229920005615 natural polymer Polymers 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 125000000962 organic group Chemical group 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 210000003101 oviduct Anatomy 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 239000000123 paper Substances 0.000 description 2
• 206010034674 peritonitis Diseases 0.000 description 2
• 239000008255 pharmaceutical foam Substances 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
• 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
• 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 2
• 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 2
• 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 2
• 229920000058 polyacrylate Polymers 0.000 description 2
• 239000004584 polyacrylic acid Substances 0.000 description 2
• 229920001281 polyalkylene Polymers 0.000 description 2
• 229920002647 polyamide Polymers 0.000 description 2
• 229920000129 polyhexylmethacrylate Polymers 0.000 description 2
• 229920000197 polyisopropyl acrylate Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 229920000182 polyphenyl methacrylate Polymers 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 229940068965 polysorbates Drugs 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 229920002635 polyurethane Polymers 0.000 description 2
• 239000004814 polyurethane Substances 0.000 description 2
• 229920000915 polyvinyl chloride Polymers 0.000 description 2
• 239000004800 polyvinyl chloride Substances 0.000 description 2
• 210000003240 portal vein Anatomy 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 229920013730 reactive polymer Polymers 0.000 description 2
• 238000004626 scanning electron microscopy Methods 0.000 description 2
• 238000004621 scanning probe microscopy Methods 0.000 description 2
• 210000003497 sciatic nerve Anatomy 0.000 description 2
• 239000003229 sclerosing agent Substances 0.000 description 2
• 239000000565 sealant Substances 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000008257 shaving cream Substances 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
• WQQPDTLGLVLNOH-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-3-sulfobutanoate Chemical class [Na+].OC(=O)CC(C([O-])=O)S(O)(=O)=O WQQPDTLGLVLNOH-UHFFFAOYSA-M 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 238000000638 solvent extraction Methods 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000001694 spray drying Methods 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 210000004304 subcutaneous tissue Anatomy 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• DIZZDZCUMBBRSG-UHFFFAOYSA-J tetrasodium;2-[[5-[3-[3-[[bis(carboxylatomethyl)amino]methyl]-4-hydroxy-2-methyl-5-propan-2-ylphenyl]-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2-hydroxy-6-methyl-3-propan-2-ylphenyl]methyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CC1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=C(CN(CC([O-])=O)CC([O-])=O)C(O)=C(C(C)C)C=2)C)=C1C DIZZDZCUMBBRSG-UHFFFAOYSA-J 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 239000002550 vasoactive agent Substances 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 210000001835 viscera Anatomy 0.000 description 2
• 235000019168 vitamin K Nutrition 0.000 description 2
• 239000011712 vitamin K Substances 0.000 description 2
• 150000003721 vitamin K derivatives Chemical class 0.000 description 2
• 229940046010 vitamin k Drugs 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229940093612 zein Drugs 0.000 description 2
• 239000005019 zein Substances 0.000 description 2
• GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
• LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
• GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
• RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
• XBPKRVHTESHFAA-LURJTMIESA-N (2s)-2-azaniumyl-2-cyclopentylacetate Chemical compound OC(=O)[C@@H](N)C1CCCC1 XBPKRVHTESHFAA-LURJTMIESA-N 0.000 description 1
• GERXSZLDSOPHJV-UHFFFAOYSA-N (4-nitrophenyl) 2-iodoacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)CI)C=C1 GERXSZLDSOPHJV-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
• FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
• FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
• VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
• POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
• VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
• SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
• CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 description 1
• RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
• VCNPGCHIKPSUSP-UHFFFAOYSA-N 2-hydroxypropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(C)O VCNPGCHIKPSUSP-UHFFFAOYSA-N 0.000 description 1
• SZVOKPKIXYMQHL-UHFFFAOYSA-N 3,6-bis[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)diazenyl]-4,5-dihydroxynaphthalene-2,7-disulfonic acid Chemical compound CN1N(C(C(=C1C)N=NC=1C(=CC2=CC(=C(C(=C2C=1O)O)N=NC=1C(N(N(C=1C)C)C1=CC=CC=C1)=O)S(=O)(=O)O)S(=O)(=O)O)=O)C1=CC=CC=C1 SZVOKPKIXYMQHL-UHFFFAOYSA-N 0.000 description 1
• DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 206010056519 Abdominal infection Diseases 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 208000004375 Angiodysplasia Diseases 0.000 description 1
• 206010060874 Aortic rupture Diseases 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 241000239290 Araneae Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 108010001478 Bacitracin Proteins 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
• 229920002284 Cellulose triacetate Polymers 0.000 description 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 206010070419 Chemical peritonitis Diseases 0.000 description 1
• 241001111317 Chondrodendron tomentosum Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 239000008709 Curare Substances 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
• IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
• 206010013530 Diverticula Diseases 0.000 description 1
• 206010013554 Diverticulum Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
• 208000035874 Excoriation Diseases 0.000 description 1
• 206010015719 Exsanguination Diseases 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 206010017826 Gastric ulcer haemorrhage Diseases 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
• 101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 1
• 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 206010030172 Oesophageal haemorrhage Diseases 0.000 description 1
• 206010030201 Oesophageal ulcer Diseases 0.000 description 1
• 206010030210 Oesophageal varices haemorrhage Diseases 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 229920002201 Oxidized cellulose Polymers 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 208000006735 Periostitis Diseases 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
• 201000005660 Protein C Deficiency Diseases 0.000 description 1
• 229940096437 Protein S Drugs 0.000 description 1
• 108010066124 Protein S Proteins 0.000 description 1
• 102000029301 Protein S Human genes 0.000 description 1
• 206010051292 Protein S Deficiency Diseases 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 206010041101 Small intestinal obstruction Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 206010041925 Staphylococcal infections Diseases 0.000 description 1
• 108010034396 Streptogramins Proteins 0.000 description 1
• 238000003917 TEM image Methods 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100031013 Transgelin Human genes 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 206010046996 Varicose vein Diseases 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
• 206010047634 Vitamin K deficiency Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 229910021536 Zeolite Inorganic materials 0.000 description 1
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
• OLDMQSKCCHULOB-SZAHLOSFSA-N [(2r,5s)-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate Chemical compound O1[C@H](COC(=O)NCCCCCCCCCCCCCCCCCC)CC[C@@H]1COP([O-])(=O)OCC[N+]1=CC=CC2=CC=CC=C12 OLDMQSKCCHULOB-SZAHLOSFSA-N 0.000 description 1
• 210000003815 abdominal wall Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000004026 adhesive bonding Methods 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 150000001345 alkine derivatives Chemical group 0.000 description 1
• 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
• 229920013820 alkyl cellulose Polymers 0.000 description 1
• 150000008051 alkyl sulfates Chemical class 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 239000002280 amphoteric surfactant Substances 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 230000000181 anti-adherent effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940030225 antihemorrhagics Drugs 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 238000007486 appendectomy Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 210000002565 arteriole Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 150000003851 azoles Chemical class 0.000 description 1
• 229960003071 bacitracin Drugs 0.000 description 1
• 229930184125 bacitracin Natural products 0.000 description 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• 229960005274 benzocaine Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 238000005460 biophysical method Methods 0.000 description 1
• 208000024330 bloating Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000010836 blood and blood product Substances 0.000 description 1
• 229940125691 blood product Drugs 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000007664 blowing Methods 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 229960003150 bupivacaine Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 229960004008 butamben picrate Drugs 0.000 description 1
• ATAGSVCDFKGYPE-UHFFFAOYSA-N butamben picrate Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1.CCCCOC(=O)C1=CC=C(N)C=C1.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ATAGSVCDFKGYPE-UHFFFAOYSA-N 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 239000011111 cardboard Substances 0.000 description 1
• 238000007675 cardiac surgery Methods 0.000 description 1
• 238000013130 cardiovascular surgery Methods 0.000 description 1
• 239000004203 carnauba wax Substances 0.000 description 1
• 235000013869 carnauba wax Nutrition 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 210000003164 cauda equina Anatomy 0.000 description 1
• 210000002434 celiac artery Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
• 229920006218 cellulose propionate Polymers 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 229960000800 cetrimonium bromide Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• LNXMADNIUWFTPP-UHFFFAOYSA-L chembl2028186 Chemical compound [Na+].[Na+].OC1=CC=C(Cl)C=C1N=NC1=C(O)C2=C(O)C=C(S([O-])(=O)=O)C=C2C=C1S([O-])(=O)=O LNXMADNIUWFTPP-UHFFFAOYSA-L 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000013626 chemical specie Substances 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 238000002192 cholecystectomy Methods 0.000 description 1
• 229960001747 cinchocaine Drugs 0.000 description 1
• PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
• 229960004022 clotrimazole Drugs 0.000 description 1
• VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 239000000512 collagen gel Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920006037 cross link polymer Polymers 0.000 description 1
• NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000006837 decompression Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 238000011257 definitive treatment Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000249 desinfective effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
• FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
• 229960001826 dimethylphthalate Drugs 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
• HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
• 238000007598 dipping method Methods 0.000 description 1
• 238000007907 direct compression Methods 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 229960000385 dyclonine Drugs 0.000 description 1
• BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000002296 dynamic light scattering Methods 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 238000012976 endoscopic surgical procedure Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 210000005081 epithelial layer Anatomy 0.000 description 1
• 208000028299 esophageal disease Diseases 0.000 description 1
• 208000019064 esophageal ulcer Diseases 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• AQRXDPFOYJSPMP-QFIPXVFZSA-N ethyl (2s)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate Chemical compound C1=CC(S(=O)(=O)N(C)[C@@H](CC(C)C)C(=O)OCC)=CC=C1CN1C2=CC=NC=C2N=C1C AQRXDPFOYJSPMP-QFIPXVFZSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229960003976 etidocaine Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005313 fatty acid group Chemical group 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 229960004884 fluconazole Drugs 0.000 description 1
• RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
• 229960004413 flucytosine Drugs 0.000 description 1
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 229940075529 glyceryl stearate Drugs 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 229960002867 griseofulvin Drugs 0.000 description 1
• DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 208000024798 heartburn Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 239000002874 hemostatic agent Substances 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 210000005161 hepatic lobe Anatomy 0.000 description 1
• 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
• 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000001624 hip Anatomy 0.000 description 1
• 230000000887 hydrating effect Effects 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 230000009878 intermolecular interaction Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000002262 irrigation Effects 0.000 description 1
• 238000003973 irrigation Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960004130 itraconazole Drugs 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 238000002684 laminectomy Methods 0.000 description 1
• 238000002357 laparoscopic surgery Methods 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 229940094506 lauryl betaine Drugs 0.000 description 1
• IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
• 229950002431 lexipafant Drugs 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 238000002690 local anesthesia Methods 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229940041033 macrolides Drugs 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229960002721 mafenide acetate Drugs 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960002409 mepivacaine Drugs 0.000 description 1
• INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
• 210000001363 mesenteric artery superior Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
• NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
• 229960002509 miconazole Drugs 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 239000002062 molecular scaffold Substances 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• QCTVGFNUKWXQNN-UHFFFAOYSA-N n-(2-hydroxypropyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCC(C)O QCTVGFNUKWXQNN-UHFFFAOYSA-N 0.000 description 1
• DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
• 239000002121 nanofiber Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000000978 natural dye Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 239000003076 neurotropic agent Substances 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 229960000988 nystatin Drugs 0.000 description 1
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
• 229920002114 octoxynol-9 Polymers 0.000 description 1
• 238000002355 open surgical procedure Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000011368 organic material Substances 0.000 description 1
• 210000003300 oropharynx Anatomy 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 229940107304 oxidized cellulose Drugs 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 239000011236 particulate material Substances 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000003460 periosteum Anatomy 0.000 description 1
• 230000008855 peristalsis Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 102000030769 platelet activating factor receptor Human genes 0.000 description 1
• 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
• 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
• 229920000139 polyethylene terephthalate Polymers 0.000 description 1
• 239000005020 polyethylene terephthalate Substances 0.000 description 1
• 229940056099 polyglyceryl-4 oleate Drugs 0.000 description 1
• 229920002959 polymer blend Polymers 0.000 description 1
• 230000000379 polymerizing effect Effects 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 229920001290 polyvinyl ester Polymers 0.000 description 1
• 229920001289 polyvinyl ether Polymers 0.000 description 1
• 229920001291 polyvinyl halide Polymers 0.000 description 1
• 210000003137 popliteal artery Anatomy 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229920003124 powdered cellulose Polymers 0.000 description 1
• 235000019814 powdered cellulose Nutrition 0.000 description 1
• 229960001896 pramocaine Drugs 0.000 description 1
• DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 229960001807 prilocaine Drugs 0.000 description 1
• MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229950003255 propoxycaine Drugs 0.000 description 1
• 229960004063 propylene glycol Drugs 0.000 description 1
• 238000011471 prostatectomy Methods 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 150000007660 quinolones Chemical class 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 239000002824 redox indicator Substances 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960001549 ropivacaine Drugs 0.000 description 1
• 238000001878 scanning electron micrograph Methods 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 208000008864 scrapie Diseases 0.000 description 1
• 238000005201 scrubbing Methods 0.000 description 1
• 229940055619 selenocysteine Drugs 0.000 description 1
• 235000016491 selenocysteine Nutrition 0.000 description 1
• ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
• 208000018316 severe headache Diseases 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 210000002832 shoulder Anatomy 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960003600 silver sulfadiazine Drugs 0.000 description 1
• UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
• 229940083037 simethicone Drugs 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 206010040872 skin infection Diseases 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 235000019832 sodium triphosphate Nutrition 0.000 description 1
• ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
• VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
• IDXHDUOOTUFFOX-UHFFFAOYSA-M sodium;2-[2-hydroxyethyl-[2-(tetradecanoylamino)ethyl]amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O IDXHDUOOTUFFOX-UHFFFAOYSA-M 0.000 description 1
• LLKGTXLYJMUQJX-UHFFFAOYSA-M sodium;3-[2-carboxyethyl(dodecyl)amino]propanoate Chemical compound [Na+].CCCCCCCCCCCCN(CCC(O)=O)CCC([O-])=O LLKGTXLYJMUQJX-UHFFFAOYSA-M 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 229940100515 sorbitan Drugs 0.000 description 1
• 229960000268 spectinomycin Drugs 0.000 description 1
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 229940041030 streptogramins Drugs 0.000 description 1
• 210000003270 subclavian artery Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 229960002317 succinimide Drugs 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000000979 synthetic dye Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• 239000003760 tallow Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
• 229960002722 terbinafine Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940040944 tetracyclines Drugs 0.000 description 1
• 239000004753 textile Substances 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229960000103 thrombolytic agent Drugs 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
• 210000003781 tooth socket Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940026752 topical sulfonamides Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000004627 transmission electron microscopy Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 210000003454 tympanic membrane Anatomy 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 208000027185 varicose disease Diseases 0.000 description 1
• 210000001177 vas deferen Anatomy 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 238000009423 ventilation Methods 0.000 description 1
• 210000000264 venule Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 239000010457 zeolite Substances 0.000 description 1
• 239000002132 β-lactam antibiotic Substances 0.000 description 1
• 229940124586 β-lactam antibiotics Drugs 0.000 description 1